首页> 外文期刊>Frontiers in Pharmacology >Ginsenoside-Rb1-Mediated Anti-angiogenesis via Regulating PEDF and miR-33a through the Activation of PPAR-γ Pathway
【24h】

Ginsenoside-Rb1-Mediated Anti-angiogenesis via Regulating PEDF and miR-33a through the Activation of PPAR-γ Pathway

机译:人参皂甙Rb1通过激活PPAR-γ途径调节PEDF和miR-33a介导的抗血管生成

获取原文
           

摘要

Angiogenesis is the formation of new blood vessels from the existing vasculature, which is involved in multiple biological processes, including atherosclerosis, ischemic heart disease, and cancer. Ginsenoside-Rb1 (Rb1), the most abundant ginsenoside isolated form Panax ginseng, has been identified as a promising anti-angiogenic agent via the up-regulation of PEDF. However, the underlying molecular mechanisms still unknown. In the present study, human umbilical vein endothelial cells (HUVECs) were selected to perform in vitro assays. Rb1 (0–20 nM) treatment induced pigment epithelial-derived factor (PEDF) protein expression in concentration and time-dependent manners. Interestingly, it was also demonstrated that the exposure of Rb1 (10 nM) could increase PEDF protein expression without any alteration on mRNA level, suggesting the involvement of posttranscriptional regulation. Furthermore, bioinformatics predictions indicated the regulation of miR-33a on PEDF mRNA 3′-UTR, which was further confirmed by luciferase reporter gene assay and real-time PCR. Over-expression of pre-miR-33a was found to regress partly Rb1-mediated PEDF increment and anti-angiogenic effect in HUVECs. Additionally, Rb1-reduced miR-33a and increased PEDF expression was prevented by pre-incubation with peroxisome proliferator-activated receptor-γ (PPAR-γ) antagonist (GW9662) or transfection with PPAR-γ siRNA in HUVECs. Taken together, our findings demonstrated that Rb1 exerted anti-angiogenic effects through PPAR-γ signaling pathway via modulating miR-33a and PEDF expressions. Thus, Rb1 may have the potential of being developed as an anti-angiogenic agent, however, further appropriate studies are warranted to evaluate the effect in vivo .
机译:血管生成是由现有脉管系统形成新血管,其涉及多种生物过程,包括动脉粥样硬化,缺血性心脏病和癌症。人参皂苷Rb1(Rb1)是人参中分离最丰富的人参皂苷,已通过PEDF的上调被鉴定为有前途的抗血管生成剂。但是,潜在的分子机制仍然未知。在本研究中,选择人脐静脉内皮细胞(HUVEC)进行体外测定。 Rb1(0–20 nM)处理以浓度和时间依赖性方式诱导色素上皮衍生因子(PEDF)蛋白表达。有趣的是,还证明了Rb1(10 nM)的暴露可以增加PEDF蛋白表达,而mRNA水平没有任何改变,表明转录后调控的参与。此外,生物信息学预测表明,miR-33a对PEDF mRNA 3'-UTR的调控,荧光素酶报告基因测定和实时PCR进一步证实了这一点。发现前miR-33a的过表达部分退还了Rb1介导的PEDF增量和HUVEC中的抗血管生成作用。此外,通过与过氧化物酶体增殖物激活的受体-γ(PPAR-γ)拮抗剂(GW9662)预先孵育或在HUVEC中用PPAR-γsiRNA转染可防止Rb1减少的miR-33a和PEDF表达增加。两者合计,我们的研究结果表明Rb1通过调节miR-33a和PEDF的表达通过PPAR-γ信号通路发挥抗血管生成作用。因此,Rb1可能具有被开发为抗血管生成剂的潜力,但是,有必要进行进一步的适当研究以评估其体内作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号